| Source:
NICOX
| Press Release | ||
| Nicox Announces Last Patients Complete Final Visit in NCX 470 Phase 3 Mont Blanc Glaucoma Trial | ||
September 19, 2022– launch at 7:30 am CET Nicox SA (Euronext Paris: FR0013018124, COX), a world ophthalmology firm, immediately introduced that the final sufferers accomplished their closing (3-month) go to in the Mont Blanc Phase 3 scientific trial of NCX 470 0.1% for the reducing of intraocular stress (IOP) in sufferers with open-angle glaucoma or ocular hypertension. A complete of 691 sufferers had been enrolled in the trial. NCX 470, Nicox’s lead scientific product candidate, is a novel, probably best-in-class, nitric oxide (NO)-donating prostaglandin analog eye drop. “We are pleased to have reached this milestone in the Mont Blanc Phase 3 clinical trial, and I would particularly like to thank our clinical sites and the Nicox development team for their incredible efforts in continuing to drive this trial to completion in the face of the COVID-19 pandemic situation.” stated Doug Hubatsch, EVP, Chief Scientific Officer of Nicox. “NCX 470 has the potential to be a best-in-class glaucoma treatment, and we look forward to sharing the topline results in early November.” Mont Blanc is a multi-regional, double-masked, 3-month, parallel group trial evaluating the efficacy and security of NCX 470 ophthalmic resolution 0.1% in comparison with latanoprost ophthalmic resolution, 0.005%. Latanoprost is probably the most extensively prescribed first-line remedy for open-angle glaucoma or ocular hypertension. The main efficacy analysis in Mont Blanc relies on time-matched IOP at 8 AM and 4 PM at Week 2, Week 6 and Month 3. The second Phase 3 trial on NCX 470, Denali, is being collectively carried out and equally financed with our Chinese associate, Ocumension Therapeutics. Topline outcomes is at the moment anticipated after 2024. |
||
| About Nicox | ||
| Nicox SA is a world ophthalmology firm creating revolutionary options to assist preserve imaginative and prescient and enhance ocular well being. Nicox’s lead program in scientific improvement is NCX 470, a novel nitric oxide-donating prostaglandin analog, for reducing intraocular stress in sufferers with open-angle glaucoma or ocular hypertension. The firm can be conducting analysis on NCX 1728, a nitric oxide-donating phosphodiesterase 5 inhibitor, in intraocular stress reducing and retinal circumstances. NCX 4251, a novel, patented, ophthalmic suspension fluticasone propionate nanocrystals for topical ocular software for dry eye illness, is being developed by Ocumension Therapeutics in China underneath an unique license settlement and is accessible for partnering elsewhere. Nicox generates income from VYZULTA® in glaucoma, licensed completely worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in a number of geographies, together with to Eyevance Pharmaceuticals, LLC (a wholly-owned subsidiary of Santen Pharmaceutical Co., Ltd.), in the U.S. and Ocumension Therapeutics in the Chinese and in the vast majority of Southeast Asian markets.
Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker image: COX) and is a part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For extra data on Nicox, its merchandise or pipeline, please go to: www.nicox.com. |
||
|
Analyst protection |
||
|
Bryan, Garnier & Co Dylan Van Haaften Paris, France |
||
| The views expressed by analysts in their protection of Nicox are these of the writer and don’t mirror the views of Nicox. Additionally, the knowledge contained in their reviews will not be right or present. Nicox disavows any obligation to right or to replace the knowledge contained in analyst reviews. | ||
|
Nicox |
Investors & Media |
|
| Forward-Looking Statements | ||
| The data contained in this doc could also be modified with out prior discover. This data consists of forward-looking statements. Such forward-looking statements will not be ensures of future efficiency. These statements are primarily based on present expectations or beliefs of the administration of Nicox S.A. and are topic to numerous components and uncertainties that would trigger precise outcomes to vary materially from these described in the forward-looking statements. Nicox S.A. and its associates, administrators, officers, workers, advisers or brokers, don’t undertake, nor have they got any obligation, to supply updates or to revise any forward-looking statements.
Risks components that are prone to have a cloth impact on Nicox’s business are offered in the third chapter of the ‘Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2021’ filed with the French Autorité des Marchés Financiers (AMF) on April 29, 2022 which is accessible on Nicox’s web site (www.nicox.com) |
||
| Nicox S.A. Drakkar 2 Bât D, 2405 route des Dolines CS 10313, Sophia Antipolis 06560 Valbonne, France T +33 (0)4 97 24 53 00 F +33 (0)4 97 24 53 99 |
||
- EN_NCX 470 MontBlanc LPLV PR_20220919
Attachments
